[Pubmed] Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis
Posté : 15 janv. 2025 12:00
Neurology. 2025 Feb 11;104(3):e210299. doi: 10.1212/WNL.0000000000210299. Epub 2025 Jan 15.
NO ABSTRACT
PMID:39813633 | DOI:10.1212/WNL.0000000000210299
Source: https://pubmed.ncbi.nlm.nih.gov/3981363 ... t9+e462414